Peroxisome proliferator-activated receptor γ ligands improve the antitumor efficacy of thrombospondin peptide ABT510

Molecular Cancer Research

Volumn 2, Issue 10, 2004, Pages 541-550

  Huang, Hanhua ^a   Campbell, Steven C ^b   Bedford, Dhugal F ^a   Nelius, Thomas ^a,c   Veliceasa, Dorina ^a   Shroff, Emelyn H ^a   Henkin, Jack ^d   Schneider, Andrew ^d   Bouck, Noel ^a   Volpert, Olga V ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CD36 ANTIGEN; CELL RECEPTOR; ENDOTHELIAL CELL RECEPTOR; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PEPTIDE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROSIGLITAZONE; THROMBOSPONDIN 1; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANTIGENS, CD36; CELLS, CULTURED; CHROMANS; DRUG INTERACTIONS; ENDOTHELIUM, VASCULAR; HUMANS; LIGANDS; MICROCIRCULATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PPAR GAMMA; PROSTAGLANDIN D2; THIAZOLIDINEDIONES; THROMBOSPONDIN 1; VASODILATOR AGENTS;

ANIMALIA;

EID: 6344235259     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
2. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996;69:135-74.
3. Koch AE. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003;62:ii60-7.
4. Campbell SC, Volpert OV, Ivanovich M, Bouck NP. Molecular mediators of angiogenesis in bladder cancer. Cancer Res 1998;58:1298-304.
5. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003;3:219-31.
6. Volpert OV, Lawler J, Bouck NP. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci U S A 1998;95:6343-8.
7. Reiher FK, Volpert OV, Jimenez B, et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 2002;98:682-9.
8. Shafiee A, Penn JS, Krutzsch HC, Inman JK, Roberts DD, Blake DA. Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1. Invest Ophthalmol Vis Sci 2000;41:2378-88.
9. Bocci G, Francia G, Man S, et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 2003;100:12917-22.
10. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997;138:707-17.
11. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6:41-8.
12. Jimenez B, Volpert OV. Mechanistic insights on the inhibition of tumor angiogenesis. J Mol Med 2001;78:663-72.
13. Volpert OV. Modulation of endothelial cell survival by an inhibitor of angiogenesis thrombospondin-1: a dynamic balance. Cancer Metastasis Rev 2000;19:87-92.
14. 1 integrin modulates endothelial cell responses to thrombospondin-1. Mol Biol Cell 2000;11:2885-900.
15. Dawson DW, Volpert OV, Pearce SF, et al. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type I repeat. Mol Pharmacol 1999;55:332-8.
16. Swerlick RA, Lee KH, Wick TM, Lawley TJ. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol 1992;148:78-83.
17. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor γ and metabolic disease. Annu Rev Biochem 2001;70:341-67.
18. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-21.
19. Murata T, He S, Hangai M, et al. Peroxisome proliferator-activated receptor-γ ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 2000;41:2309-17.
20. Panigrahy D, Singer S, Shen LQ, et al. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002;110:923-32.
21. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 1998;93:229-40.
22. Reiher FK, Ivanovich M, Huang H, Smith ND, Bouck NP, Campbell SC. The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer. J Urol 2001;165:2075-81.
23. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8:349-57.
24. Guo N, Krutzsch HC, Inman JK, Roberts DD. Thrombospondin 1 and type I repeat peptides of thrombospondin I specifically induce apoptosis of endothelial cells. Cancer Res 1997;57:1735-42.
25. Wintergerst ES, Jelk J, Rahner C, Asmis R. Apoptosis induced by oxidized low density lipoprotein in human monocyte-derived macrophages involves CD36 and activation of caspase-3. Eur J Biochem 2000;267:6050-9.
26. Juge-Aubry C, Pernin A, Favez T, et al. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5′-flanking region. J Biol Chem 1997;272:25252-9.
27. Sato O, Kuriki C, Fukui Y, Motojima K. Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor α and γ ligands. J Biol Chem 2002;277:15703-11.
28. Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPAR γ associated with human colon cancer. Mol Cell 1999;3:799-804.
29. Goetze S, Bungenstock A, Czupalla C, et al. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARγ-ligands. Hypertension 2002;40:748-54.
30. 12,14-prostaglandin J2. J Biol Chem 1999;274:17042-8.
31. Clay CE, Monjazeb A, Thorburn J, Chilton FH, High KP. 15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells. J Lipid Res 2002;43:1818-28.
32. Fauconnet S, Lascombe I, Chabannes E, et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator- activated receptors in bladder cancer cells. J Biol Chem 2002;277:23534-43.
33. Jozkowicz A, Dulak J, Piatkowska E, Placha W, Dembinska-Kiec A. Ligands of peroxisome proliferator-activated receptor-γ increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages. Acta Biochim Pol 2000;47:1147-57.
34. Filleur S, Volpert OV, Degeorges A, et al. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev 2001;15:1373-82.
35. Yu JL, Coomber BL, Kerbel RS. A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation 2002;70:599-609.
36. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998;93:241-52.
37. Collins AR. Pleiotropic vascular effects of PPARγ ligands. Drug News Perspect 2003;16:197-204.
38. Lundholt BK, Scudder KM, Pagliaro L. A simple technique for reducing edge effect in cell-based assays. J Biomol Screen 2003;8:566-70.
39. Chlenski A, Ketels KV, Tsao MS, et al. Tight junction protein ZO-2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma. Int J Cancer 1999;82:137-44.
40. Polverini PJ, Bouck NP, Rastinejad F. Assay and purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol 1991;198:440-50.
41. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996;37:1625-32.
42. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991;19:2499.
43. Martinez-Irujo JJ, Villahermosa ML, Alberdi E, Santiago E. A checkerboard method to evaluate interactions between drugs. Biochem Pharmacol 1996;51:635-44.
44. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981;115:207-16.